US5882676A
(en)
*
|
1995-05-26 |
1999-03-16 |
Alza Corporation |
Skin permeation enhancer compositions using acyl lactylates
|
US6512010B1
(en)
*
|
1996-07-15 |
2003-01-28 |
Alza Corporation |
Formulations for the administration of fluoxetine
|
US6203817B1
(en)
|
1997-02-19 |
2001-03-20 |
Alza Corporation |
Reduction of skin reactions caused by transdermal drug delivery
|
US5968547A
(en)
*
|
1997-02-24 |
1999-10-19 |
Euro-Celtique, S.A. |
Method of providing sustained analgesia with buprenorphine
|
US6660295B2
(en)
|
1997-09-30 |
2003-12-09 |
Alza Corporation |
Transdermal drug delivery device package with improved drug stability
|
US6699497B1
(en)
|
1998-07-24 |
2004-03-02 |
Alza Corporation |
Formulations for the transdermal administration of fenoldopam
|
US6348210B1
(en)
|
1998-11-13 |
2002-02-19 |
Alza Corporation |
Methods for transdermal drug administration
|
EP1140039B1
(en)
|
1998-12-18 |
2009-11-04 |
Alza Corporation |
Transparent transdermal nicotine delivery devices
|
AU3536799A
(en)
*
|
1999-04-26 |
2000-11-10 |
Lead Chemical Co., Ltd. |
Percutaneous preparations containing oxybutynin
|
US6562368B2
(en)
|
1999-12-16 |
2003-05-13 |
Dermatrends, Inc. |
Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
|
US6582724B2
(en)
*
|
1999-12-16 |
2003-06-24 |
Dermatrends, Inc. |
Dual enhancer composition for topical and transdermal drug delivery
|
US6673363B2
(en)
|
1999-12-16 |
2004-01-06 |
Dermatrends, Inc. |
Transdermal and topical administration of local anesthetic agents using basic enhancers
|
US6586000B2
(en)
|
1999-12-16 |
2003-07-01 |
Dermatrends, Inc. |
Hydroxide-releasing agents as skin permeation enhancers
|
US20030104041A1
(en)
*
|
1999-12-16 |
2003-06-05 |
Tsung-Min Hsu |
Transdermal and topical administration of drugs using basic permeation enhancers
|
US6783294B2
(en)
|
2000-02-14 |
2004-08-31 |
Johnson & Johnson Consumer Companies, Inc. |
Solid cleanser holder
|
US6607739B1
(en)
|
2000-02-14 |
2003-08-19 |
Johnson & Johnson Consumer Companies, Inc. |
Dispensing article
|
US6436428B1
(en)
|
2000-03-21 |
2002-08-20 |
Enhance Pharmaceuticals, Inc. |
Device and method for treating urinary incontinence in females
|
US7029694B2
(en)
*
|
2000-04-26 |
2006-04-18 |
Watson Laboratories, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
AU2001253782B2
(en)
*
|
2000-04-26 |
2006-06-29 |
Allergan Sales, Llc |
Minimizing adverse experience associated with oxybutynin therapy
|
US20030124177A1
(en)
*
|
2000-04-26 |
2003-07-03 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
US7179483B2
(en)
*
|
2000-04-26 |
2007-02-20 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
US20020119187A1
(en)
*
|
2000-09-29 |
2002-08-29 |
Cantor Adam S. |
Composition for the transdermal delivery of fentanyl
|
US20020198215A1
(en)
*
|
2000-10-23 |
2002-12-26 |
Lino Tavares |
Terazosin transdermal device and methods
|
US7988991B2
(en)
*
|
2001-03-07 |
2011-08-02 |
Hisamitsu Pharmaceutical Co., Inc. |
Adhesive patch
|
DE10237057A1
(de)
*
|
2002-08-09 |
2004-03-25 |
Grünenthal GmbH |
Opioid-Rezeptor-Antagonisten in Pflasterformulierungen
|
JP4354678B2
(ja)
*
|
2002-08-28 |
2009-10-28 |
久光製薬株式会社 |
貼付剤
|
US20040258742A1
(en)
*
|
2003-04-11 |
2004-12-23 |
Van Osdol William Woodson |
Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines
|
DE60303854T2
(de)
|
2003-11-11 |
2006-08-10 |
Mattern, Udo |
Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen
|
US8784869B2
(en)
|
2003-11-11 |
2014-07-22 |
Mattern Pharma Ag |
Controlled release delivery system for nasal applications and methods of treatment
|
US20050234024A1
(en)
*
|
2004-04-14 |
2005-10-20 |
Clarke David E |
Materials and methods for the treatment of ulcerative colitis
|
JP2005325165A
(ja)
*
|
2004-05-12 |
2005-11-24 |
Three M Innovative Properties Co |
100℃以下の温度で溶融塗布可能なヨウ素含有ホットメルト粘着剤および該粘着剤を用いた医療用粘着シート製品
|
US20070082039A1
(en)
*
|
2004-10-18 |
2007-04-12 |
Jones Gerald S Jr |
Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids
|
CA2583642C
(en)
|
2004-10-21 |
2013-06-25 |
Durect Corporation |
Transdermal delivery systems
|
US8252320B2
(en)
|
2004-10-21 |
2012-08-28 |
Durect Corporation |
Transdermal delivery system for sufentanil
|
US20070087055A1
(en)
*
|
2005-10-14 |
2007-04-19 |
David Jan |
Directly compressible extended release alprazolam formulation
|
WO2007046102A2
(en)
|
2005-10-19 |
2007-04-26 |
Menni Menashe Zinger |
Methods for the treatment of hyperhidrosis
|
EP1986618A2
(en)
*
|
2006-02-13 |
2008-11-05 |
Aveva Drug Delivery Systems, Inc. |
Adhesive preparation comprising sufentanil and methods of using the same
|
US8518926B2
(en)
*
|
2006-04-10 |
2013-08-27 |
Knopp Neurosciences, Inc. |
Compositions and methods of using (R)-pramipexole
|
WO2007121188A2
(en)
*
|
2006-04-10 |
2007-10-25 |
Knopp Neurosciences, Inc. |
Compositions and methods of using r(+) pramipexole
|
JP5122445B2
(ja)
|
2006-05-08 |
2013-01-16 |
帝國製薬株式会社 |
抗認知症薬物の経皮吸収製剤
|
ATE537826T1
(de)
*
|
2006-05-16 |
2012-01-15 |
Knopp Neurosciences Inc |
Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
|
PL2068825T3
(pl)
|
2006-10-04 |
2011-06-30 |
M & P Patent Ag |
Układ dostarczania o kontrolowanym uwalnianiu do donosowego podawania związków neuroprzekaźnikowych
|
US8524695B2
(en)
*
|
2006-12-14 |
2013-09-03 |
Knopp Neurosciences, Inc. |
Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
|
US8519148B2
(en)
*
|
2007-03-14 |
2013-08-27 |
Knopp Neurosciences, Inc. |
Synthesis of chirally purified substituted benzothiazole diamines
|
US20090291127A1
(en)
*
|
2008-05-21 |
2009-11-26 |
Jianye Wen |
Transdermal anti-dementia active agent formulations and methods for using the same
|
US20110190356A1
(en)
*
|
2008-08-19 |
2011-08-04 |
Knopp Neurosciences Inc. |
Compositions and Methods of Using (R)- Pramipexole
|
JP2012504163A
(ja)
*
|
2008-09-30 |
2012-02-16 |
テイコク ファーマ ユーエスエー インコーポレーテッド |
経皮持続送達ドネペジル組成物および該組成物を使用する方法
|
WO2010054495A2
(en)
*
|
2008-11-14 |
2010-05-20 |
Profimed S.R.O. |
Non-aqueous colloidal formulation
|
US8920392B2
(en)
|
2009-05-05 |
2014-12-30 |
Watson Laboratories, Inc. |
Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
|
DE102009022915A1
(de)
*
|
2009-05-27 |
2010-12-09 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System mit gesteuertem Wirkstofffluss
|
JP2012530723A
(ja)
*
|
2009-06-19 |
2012-12-06 |
ノップ ニューロサイエンシーズ、インク. |
筋萎縮性側索硬化症を治療するための組成物及び方法
|
US20100178307A1
(en)
*
|
2010-01-13 |
2010-07-15 |
Jianye Wen |
Transdermal anti-dementia active agent formulations and methods for using the same
|
CN106390128B
(zh)
|
2011-01-10 |
2022-07-08 |
伊沃恩有限公司 |
β-肾上腺素能反向激动剂用于戒烟的用途
|
US9757388B2
(en)
|
2011-05-13 |
2017-09-12 |
Acerus Pharmaceuticals Srl |
Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
|
US20130040923A1
(en)
|
2011-05-13 |
2013-02-14 |
Trimel Pharmaceuticals Corporation |
Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
|
US20130045958A1
(en)
|
2011-05-13 |
2013-02-21 |
Trimel Pharmaceuticals Corporation |
Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
|
KR102014565B1
(ko)
*
|
2011-12-12 |
2019-08-26 |
에르테에스 로만 테라피-시스테메 아게 |
부프레노르핀을 포함하는 경피 전달 시스템
|
WO2013096816A1
(en)
|
2011-12-22 |
2013-06-27 |
Biogen Idec Ma Inc. |
Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
|
US9074972B2
(en)
|
2012-05-16 |
2015-07-07 |
Dionex Corporation |
Surrogate addition device and a method of analyte concentration
|
CN103919754B
(zh)
*
|
2013-01-15 |
2018-11-06 |
江苏康倍得药业股份有限公司 |
奥昔布宁药物组合物及其应用
|
US9006462B2
(en)
|
2013-02-28 |
2015-04-14 |
Dermira, Inc. |
Glycopyrrolate salts
|
US9662313B2
(en)
|
2013-02-28 |
2017-05-30 |
Knopp Biosciences Llc |
Compositions and methods for treating amyotrophic lateral sclerosis in responders
|
EP3473615B1
(en)
|
2013-02-28 |
2022-01-19 |
Journey Medical Corporation |
Glycopyrrolate salts
|
US11744838B2
(en)
|
2013-03-15 |
2023-09-05 |
Acerus Biopharma Inc. |
Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
|
WO2014188329A2
(en)
|
2013-05-20 |
2014-11-27 |
Mylan, Inc. |
Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders
|
PT3019167T
(pt)
|
2013-07-12 |
2021-03-04 |
Knopp Biosciences Llc |
Tratamento de níveis elevados de eosinófilos e/ou basófilos
|
US9468630B2
(en)
|
2013-07-12 |
2016-10-18 |
Knopp Biosciences Llc |
Compositions and methods for treating conditions related to increased eosinophils
|
US9642840B2
(en)
|
2013-08-13 |
2017-05-09 |
Knopp Biosciences, Llc |
Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
|
AU2014306597B2
(en)
|
2013-08-13 |
2018-05-17 |
Knopp Biosciences Llc |
Compositions and methods for treating chronic urticaria
|
US20150098997A1
(en)
|
2013-10-07 |
2015-04-09 |
Teikoku Pharma Usa, Inc. |
Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
|
RU2018105761A
(ru)
*
|
2013-10-07 |
2019-02-26 |
ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. |
Устройства для трансдермальной доставки дексмедетомидина и способы их применения
|
KR101891185B1
(ko)
|
2013-10-07 |
2018-08-24 |
테이코쿠 팔마 유에스에이, 인코포레이티드 |
비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
|
CN104666279A
(zh)
*
|
2013-11-28 |
2015-06-03 |
上海现代药物制剂工程研究中心有限公司 |
载药的三维网状立体构型的透皮给药制剂及其制备方法
|
WO2016112263A1
(en)
|
2015-01-09 |
2016-07-14 |
Chase Pharmaceuticals Corporation |
Oxybutynin transdermal therapeutic system combination
|
MX2018008190A
(es)
|
2015-12-30 |
2018-11-12 |
Corium Int Inc |
Sistemas y metodos para la administracion transdermica a largo plazo.
|
WO2017223402A1
(en)
|
2016-06-23 |
2017-12-28 |
Corium International, Inc. |
Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
|
AU2017301929B2
(en)
|
2016-07-27 |
2023-03-02 |
Corium Pharma Solutions, Inc. |
Memantine transdermal delivery systems
|
US9993466B2
(en)
|
2016-07-27 |
2018-06-12 |
Corium International, Inc. |
Donepezil transdermal delivery system
|
WO2019023499A1
(en)
*
|
2017-07-26 |
2019-01-31 |
Corium International, Inc. |
TRANSDERMAL DELIVERY SYSTEM WITH MICROPOROUS MEMBRANE HAVING SOLVENT FILLED PORES
|
AU2018392686A1
(en)
|
2017-12-20 |
2020-07-09 |
Corium Pharma Solutions, Inc. |
Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
|
WO2023069778A1
(en)
*
|
2021-10-22 |
2023-04-27 |
Georgetown University |
Non-invasive and passive transdermal drug delivery patch for parkinson's disease
|